Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

HEXARELIN

The most potent of the GHRP family per microgram, but it also burns out its own receptors fastest. Run it in short, hard cycles, not continuously.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

The most potent of the GHRP family per microgram, but it also burns out its own receptors fastest.

Run it in short, hard cycles, not continuously.

What It Does

Hexarelin is a highly potent GHS-R1a agonist with the strongest GH-releasing punch of the GHRPs and minimal appetite effect.

Its high binding affinity drives the fastest receptor desensitization of any GHRP, so its window of usefulness is short.

Mild cortisol/prolactin rise; some cardioprotective signaling in research.

Reconstitution

Vial SizeBAC Water / SolventConcentration
2 mg+ 1 mL2 mg/mL
5 mg+ 2.5 mL2 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–61–2×/day100 mcgWorking dose. ~1 mcg/kg saturates; do not chase higher. Fasted.
Off6–8 weeks–Longer off than other GHRPs, receptors need more time to re-sensitize.
Cycle & Timing

4–6 weeks on / 6–8 weeks off (shorter on, longer off than other GHRPs). Running it longer cuts response by 45%+ as receptors downregulate.

Timing

Empty stomach, AM and/or pre-bed. Saturation: ~1 mcg/kg, higher doses accelerate desensitization without more GH.

Population Considerations

Women are less responsive to GH (need more), and these ghrelin-types give a bigger GH bump in women; but they raise prolactin, which can disrupt the cycle/ovulation (watch for missed periods). Oral estrogen also blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal). High prolactin from GHRPs lowers libido and testosterone in men, switch to a clean option if it cli Women are less responsive to GH (need more), and these ghrelin-types give a bigger GH bump in women; but they raise prolactin, which can disrupt the cycle/ovulation (watch for missed periods). Oral estrogen also blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal). High prolactin from GHRPs lowers libido and testosterone in men, switch to a clean option if it climbs.

Handling & Stacking

Injection site
SubQ, abdomen. Rotate.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~3–4 weeks (structure-based estimate, no published data).
Side effects
Flushing, water retention, mild cortisol/prolactin rise. Diminishing response is the main practical limit.
What to expect
  • Fast, strong GH response early in the cycle; benefit tapers as receptors desensitize; hence short cycles.
  • Minimal appetite vs GHRP-6.
  • Supply math 2mg → 5 vials | 5mg → 2 vials (6-wk @ 100 mcg × 2/day)
Pairs well with
CJC-1295 (No DAC) / Sermorelin (GHRH synergy for the short cycle); Ipamorelin (rotate to after the hexarelin block)
Avoid
Active malignancy. Severe insulin resistance. Continuous / long-term use (desensitization). Stacking with other GHRPs simultaneously
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label) Pregnancy and lactation
Warnings
Fastest receptor desensitization of any GHRP, short cycles are mandatory, not optional Cortisol and prolactin elevation Insulin resistance with sustained use Fluid retention, carpal tunnel, joint pain IGF-1 elevation: theoretical malignancy promotion beyond physiological ranges
Drug interactions
Glucocorticoids: blunt GH response Insulin / antidiabetics: GH worsens insulin resistance, monitor glucose Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1
Labs
  • IGF-1 (baseline + end of the short cycle) Fasting glucose / HbA1c (baseline + end) Prolactin if symptomatic Age-appropriate cancer screening before starting Out of range?
  • IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
Stop criteria
Response clearly fading (expected, end the cycle and take the full off period) Fasting glucose rises >20 mg/dL above baseline IGF-1 above upper limit of normal for age New joint pain, carpal tunnel, or vision changes
Patient education
Treat this as a short-cycle tool, it desensitizes faster than any other GHRP Don’t increase the dose to fight fading response; take the off period instead Fasted dosing; protect sleep Not for use during active malignancy or pregnancy; report new lumps or vision changes
References
researchdosing · peptidedosages · PubMed · thepeptidereport · Span 2000 · Weissberger 1991